Not sure why this is surging. This pharma has very low capitalization, and a very limited population for its pipeline drugs. What is the primary catalyst and drug that makes this a high potential company?
I said the same thing on another post. Was looking to get in. I just do not see a great upside.
Its a rare autoimmune disease w/muscle weakness already approved in EU! Hello??
But the total people that suffer from that ailment seems very low. Also, on the drug res maj dep disorder, still a long way to go...not shorty, just trying to understand a buy move.
Sheff in Ihub got this going. Big influence in a very dangerous sector. Make your money and get the hell out.
Drug resistant major depressive disorder has a limited population?